Is migraine a contraindication for deep transcranial magnetic stimulation (deep TMS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Is Migraine a Contraindication for Deep TMS?

No, migraine is not a contraindication for deep transcranial magnetic stimulation (deep TMS); in fact, deep TMS is an emerging treatment option for migraine, particularly in treatment-resistant cases.

Deep TMS as a Treatment for Migraine

Deep TMS has been studied specifically as an add-on therapy for chronic migraine in patients who have failed standard pharmacological treatments. The evidence demonstrates that migraine patients can safely receive deep TMS, and it may actually provide therapeutic benefit 1.

Evidence Supporting Safety and Efficacy

A preliminary study evaluated high-frequency deep TMS (10 Hz, 600 pulses in 10 trains) targeting the dorsolateral prefrontal cortex (DLPFC) bilaterally in treatment-resistant chronic migraine patients. The treatment was:

  • Well tolerated with no serious adverse events
  • Associated with significant reduction in:
    • Pain intensity
    • Frequency of attacks
    • Analgesic overuse
    • Depressive symptoms

These benefits persisted during treatment and one month after completion 1.

General TMS Safety Profile in Migraine

Broader evidence on transcranial magnetic stimulation in migraine confirms its safety profile:

  • Minimal adverse effects, primarily mild headaches
  • Very rare risk of single provoked seizures
  • TMS devices are actually FDA-marketed for migraine treatment in the United States 2

The main absolute contraindications for TMS are:

  • Nearby ferromagnetic implants
  • Electronic implants (e.g., cochlear implants, pacemakers)
  • Infection at the stimulation site 2

Clinical Context

Recent guidelines acknowledge non-invasive neuromodulatory devices (which include TMS) as legitimate options for migraine prevention, particularly when medication is contraindicated or has failed 3. Multiple systematic reviews support TMS as a promising neuromodulatory approach for migraine management, though they note the need for larger standardized trials 4, 5.

Important Caveats

  • Deep TMS for migraine is best positioned as add-on therapy in treatment-resistant cases rather than first-line treatment
  • The evidence base, while promising, still requires larger randomized controlled trials with standardized protocols
  • Treatment parameters (frequency, intensity, target location, number of sessions) vary across studies and should be individualized based on available protocols 4, 5

In summary: Not only is migraine not contraindicated for deep TMS, but deep TMS represents a safe and potentially effective treatment option for chronic migraine patients who have not responded adequately to standard pharmacological therapies.

Related Questions

What is the textbook definition of a migraine?
Can analgesic use exacerbate migraine headaches?
What is the appropriate evaluation and management for a 28-year-old woman with a two-year history of chronic migraine-type headaches (headache, nausea, photophobia, phonophobia) who receives monthly emergency department injections?
What are the 2025 American Headache Society guidelines for emergency department management of migraine?
What is the recommended acute treatment for the aura phase of migraine?
What is the appropriate management for a 58‑year‑old man with symptomatic urinary tract infection, urinalysis showing 2+ blood, moderate bacteria, and 5–10 red blood cells without gross hematuria?
What are the appropriate doses of acetaminophen (Tylenol) and ibuprofen for a 10-year-old female weighing 42 kg who has a headache?
At what hemoglobin level can primaquine be initiated in a patient with normal glucose‑6‑phosphate dehydrogenase (G6PD) activity?
Is the provided impression and management plan appropriate for a 32-year-old female presenting for an annual physical with acute viral upper respiratory infection (dry cough, sinus congestion, headache), anxiety refractory to fluoxetine, heavy menstrual bleeding with irregular cycles and new facial/neck hirsutism, and obesity (BMI 30.1)?
How should persistent facial tics be managed in a 12‑year‑old with Tourette’s syndrome after discontinuing escitalopram (Lexapro) and atomoxetine (Strattera)?
Which antihistamines should be avoided in patients with arrhythmia, including those with congenital long‑QT syndrome or on other QT‑prolonging drugs?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.